Immatics NVIMTX -3.69%60 PB Ratio is 2.50 as of Jun. 25, 2026, which is 29% below its 10-year median of 3.52. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Immatics NV ranks better than 53.04% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Immatics NV's share price is $9.65. Immatics NV's Book Value per Share for the quarter that ended in Mar. 2026 was $3.86. Hence, Immatics NV's PB Ratio of today is 2.50.
The historical rank and industry rank for Immatics NV's PB Ratio or its related term are showing as below:
IMTX'
s PB Ratio Range Over the Past 10 Years
Min: 0.73 Med: 3.52 Max: 31.11
Current: 2.5
During the past 8 years, Immatics NV's highest PB Ratio was 31.11. The lowest was 0.73. And the median was 3.52.
IMTX's PB Ratio is ranked better than 53.04% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs IMTX: 2.50
During the past 12 months, Immatics NV's average Book Value Per Share Growth Rate was -19.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 40.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Immatics NV was 125.50% per year. The lowest was 14.60% per year. And the median was 18.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Immatics NV PB Ratio Related Terms
Immatics NV PB Ratio Historical Data
* Premium members only.
The historical data trend for Immatics NV's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immatics NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where Immatics NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Immatics NV's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Immatics NV (IMTX) has a PB Ratio of 2.50 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Immatics NV and its competitors. This is 29% below median its historical median of 3.52. Over the past decade, Immatics NV's PB Ratio has ranged from 0.73 to 31.11. According to the industry distribution chart, Immatics NV ranks #579 out of 1233 companies in the Biotechnology industry, placing it in the top 47%.
Is Immatics NV's PB Ratio too high?
Immatics NV's current PB Ratio of 2.50 is 29% below median its 10-year median of 3.52. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 31.11. The Biotechnology industry median PB Ratio is 2.80. Immatics NV's value of 2.50 is 10.7% below this industry median. Based on the distribution chart, Immatics NV ranks #579 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's PB Ratio compare to INVA and PGEN?
According to the Biotechnology industry distribution chart, Immatics NV ranks #579 out of 1233 companies for PB Ratio. This puts Immatics NV in the upper half of its industry. The industry median PB Ratio is 2.80. Immatics NV's value of 2.50 is 10.7% below this benchmark. Historically, Immatics NV's own PB Ratio has ranged from 0.73 to 31.11 over the past decade. While the company's 10-year median is 3.52 vs. the industry median of 2.80, Immatics NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immatics NV's current PB Ratio of 2.50 is 10.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Immatics NV and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immatics NV's current PB Ratio is 2.50, which is 29% below median its own 10-year median of 3.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.57, compared to a current price of $9.65 — trading 170.3% above its estimated fair value. The current PB Ratio is 2.50, which is 29% below median its 10-year median of 3.52 and 10.7% below the Biotechnology industry median of 2.80. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Immatics NV (IMTX), the current PB Ratio is 2.50 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $9.65 is trading 170.3% above its estimated GF Value™ of $3.57.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
PB Ratio: 2.50 (29% below median its 10-year median of 3.52)
GF Value™: $3.57 vs. price of $9.65 (170.3% above fair value)
Industry Position: 10.7% below the Biotechnology median (#579 of 1233)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score
Get the complete analysis for IMTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
